GHK-Cu: A Copper Carrier for the Repair Matrix

The short version

GHK-Cu stands for Glycyl-L-Histidyl-L-Lysine Copper(II) complex. It is a very small peptide — three amino acids: glycine, histidine, lysine — bound to a single copper ion. You will also see it called copper tripeptide-1. The same GHK sequence occurs naturally inside type I collagen, the main structural protein of skin and tendon, which is a clue to what it does: it signals skin and connective-tissue cells to rebuild their collagen-and-elastin scaffolding ^[4][6].

Of the three peptides here, GHK-Cu has the most human evidence. The catch is that almost all of it is topical — creams and serums applied to the skin surface — and the peptide does not cross intact skin particularly well on its own ^[1]. Topical copper-peptide cosmetics are legal and widely sold; injectable or systemic use is unapproved and research-only ^[1]. This page summarizes the studies and recommends no dose or regimen.

What it is

GHK-Cu is a linear tripeptide, glycyl-L-histidyl-L-lysine, chelated — bound in a stable, claw-like grip — one-to-one to a copper(II) ion. The copper is anchored by the histidine imidazole ring, the glycine amino group, and a deprotonated backbone nitrogen, leaving the lysine side chain free. The complex carries a small positive charge.

The bare GHK sequence appears endogenously within the alpha-2(I) chain of type I collagen and in a matrix protein called SPARC/osteonectin — so the body already uses this motif. Copper coordination is required for most of GHK's reported bioactivities, which is why the free tripeptide (GHK) and the copper complex (GHK-Cu) should not be treated as identical ^[4].

How it works

GHK-Cu plays two roles at once: it is a copper chaperone (delivering copper where it is needed) and a broad signaling molecule. At very low — picomolar to nanomolar — concentrations, it directly tells dermal fibroblasts, the skin's matrix-making cells, to synthesize collagen, elastin, glycosaminoglycans, and the proteoglycan decorin. Simultaneously it rebalances the enzymes that break matrix down (matrix metalloproteinases) against their natural inhibitors (TIMPs) ^[6]. The copper ion itself enables lysyl-oxidase-mediated cross-linking that knits the new collagen and elastin together, plus a superoxide-dismutase-like antioxidant action.

Its effects extend to the gene level. A Connectivity Map analysis reported that GHK shifts expression of roughly 31.2% of human genes at a 50%-or-greater change threshold — about 59% upward, 41% downward — strongly stimulating protein-quality-control (ubiquitin-proteasome) and DNA-repair programs ^[2]. An honest note belongs here: the widely quoted "~4,000 genes" figure is an extrapolation; the verified 50%-threshold table reports on the order of 2,100 genes ^[2].

What the research shows

Collagen and skin regeneration. The canonical review documents GHK-Cu stimulating synthesis of collagen, dermatan sulfate, chondroitin sulfate, and decorin. It notes that plasma GHK falls from roughly 200 ng/mL at age 20 to about 80 ng/mL by age 60, and reports that topical GHK-Cu increased collagen production in 70% of treated women, outperforming vitamin C (50%) and retinoic acid (40%) ^[4].

Gene expression. The 2018 Connectivity Map analysis quantified the broad transcriptomic shift toward tissue-repair, protein-quality-control, DNA-fidelity, and antioxidant programs ^[2].

In vitro foundation. In human fibroblast cultures, GHK-Cu stimulated collagen synthesis beginning at concentrations of 10⁻¹² to 10⁻¹¹ M, peaking at 10⁻⁹ M, with no change in cell number — indicating a specific metabolic effect, not simply more cells ^[7].

A controlled human signal. In a 6-month trial of 45 men with androgenetic alopecia (male-pattern hair loss), a complex of 5-aminolevulinic acid and glycyl-histidyl-lysine peptide increased hair count by 52.6 (at 100 mg/mL) and 71.5 (at 50 mg/mL) compared with only 9.6 for placebo, with no adverse events — the strongest controlled human efficacy signal for a GHK-containing topical, though it used a combination product rather than pure GHK-Cu ^[3].

The delivery problem. A 2025 review confirms that GHK's poor stratum-corneum permeability (clogP of -2.24) is the central formulation challenge. It evaluates palmitoylation (raising clogP to 1.14) and microneedle pretreatment, which allowed about 134 nmol GHK to permeate versus none through intact skin, as practical enhancement strategies ^[1]. A separate human-skin-penetration study quantified copper delivery from GHK-Cu through layered dermatomed skin, with measurable dermal copper accumulation forming over 48 hours ^[5].

Reported effects, cautions & safety

Topical copper-peptide products carry a long real-world safety record. Several cautions are well documented:

• No approved drug indication. There is no FDA- or EMA-approved therapeutic GHK-Cu product by any route. Topical copper tripeptide-1 is a legal cosmetic ingredient; injectable or systemic use is unapproved and research-only ^[1].
• Thin human evidence beyond skin. Clinical data are limited to small topical dermatology trials and one 45-patient combination hair-loss study. No validated human pharmacokinetic data exist for injectable or systemic GHK-Cu, so community dosing protocols have no peer-reviewed basis ^[3].
• Localized hyperpigmentation. Skin darkening has been reported with some topical copper-peptide applications — approximately 40% incidence in one acne-scar microneedling context.
• Formulation incompatibility. Vitamin C and low-pH acids can destroy both actives through copper interactions — a practical formulation and user-error risk.
• Theoretical copper accumulation. Prolonged systemic use raises a theoretical copper-balance concern, though no human copper-toxicity cases attributed to GHK-Cu appear in the peer-reviewed record.
• Single-investigator origin. A large share of the foundational mechanistic literature comes from one investigator and colleagues, which limits independent replication of the broader gene-expression and anti-aging claims ^[2].

Where it fits in recovery research

GHK-Cu is the matrix-and-skin specialist on this desk, and the one with the strongest human footing — but that footing is mostly on the skin surface, where its own delivery problem caps how far the evidence reaches ^[1]. Where TB-500 and BPC-157 live almost entirely in animal models, GHK-Cu has decades of topical cosmetic use behind it. What it still lacks is validated systemic human data. It rounds out the repair picture with the scaffolding angle: the actual rebuilding of collagen and elastin. Compare all three on the comparison page.